Dose escalation study of OMO-103, a first in class Pan-MYC-Inhibitor in patients (pts) with advanced solid tumors by Garralda, E., Moreno, V., Alonso, G., Corral, E., Hernandez-Guerrero, T., Ramon, J., Doger de Spéville, B., Martinez, E., Soucek, L., Niewel, M., Calvo, E.

Get full text

132 (PB120): Pharmacokinetic and pharmacodynamic analyses of OMO-103 in preclinical and patient tissues by Martín, S. Martínez, Casacuberta-Serra, S., López-Estévez, S., Foradada, L., Cano, V. Castillo, Kaur, J., Thabussot, H., Morales, J., Niewel, M., Nonell, L., Arqués, O., Beaulieu, M.E., Soucek, L.

Get full text

MYC inhibition by OMO-103 induces immune cell recruitment in preclinical models of NSCLC and modulates the cytokine and chemokine profiles of Phase I patients showing stable diseas... by Casacuberta Serra, S., Martínez-Martín, S., González-Larreategui, Í., López-Estévez, S., Jauset, T., Zacarías-Fluck, M., Massó-Vallés, D., Martín, G., Foradada, L., Grueso, J., Serrano, E., Thabussot, H., Castillo Cano, V., Whitfield, J.R., Morales, J., Niewel, M., Beaulieu, M.E., Soucek, L.

Get full text